Abstract
Psychotic symptoms, defined as the occurrence of delusions or hallucinations, are frequent in Alzheimer disease (AD with psychosis, AD+P), affecting ~ 40% to 60% of individuals with AD. AD+P identifies a subgroup of AD patients with poor outcomes. The strongest clinical predictor of AD+P is a greater degree of cognitive impairment than in AD subjects without psychosis (AD-P). Other frequently replicated correlates of AD+P include elevated depressive symptoms. Although the estimated heritability of psychosis in AD is 61%, the underlying genetic sources of this risk are not known. We report a genome-wide meta-analysis of 12,317 AD subjects, with and without psychosis. Results showed common genetic variation accounted for a significant portion of heritability. Two loci, one in the gene ENPP6 (best SNP rs9994623, O.R. (95%CI) 1.16 (1.10, 1.22), p=1.26×10-8) and one spanning the 3’-UTR of an alternatively spliced transcript of SUMF1 (best SNP rs201109606, O.R. 0.65 (0.56-0.76), p=3.24×10-8), had genome-wide significant associations with the risk of psychosis in AD. Psychosis risk in AD demonstrated negative genetic correlations with cognitive and educational attainment and positive genetic correlation with depressive symptoms. We had previously observed a negative genetic correlation with schizophrenia, instead we now found a stronger negative correlation with the related phenotype of bipolar disorder. Psychosis risk in AD was not genetically correlated with AD or other neurodegenerative diseases. These findings provide the first unbiased identification of the association of psychosis in AD with common genetic variation and provide insights into its genetic architecture. Study of the genetic mechanisms underlying the associations of loci in ENPP6 and SUMF1 with psychosis in AD are warranted.
Competing Interest Statement
Yushi Liu and Basavaraj Hooli are currently employed by and holding stock in Eli Lilly and Company. Dr. Clive Ballard reports grants and personal fees from Acadia pharmaceutical company, grants and personal fees from Lundbeck, personal fees from Roche, personal fees from Otsuka, personal fees from Biogen, personal fees from Eli Lilly, personal fees from Novo Nordisk, personal fees from AARP, grants and personal fees from Synexus, personal fees from Exciva, outside the submitted work. Dr. Oscar Lopez served as a consultant for Grifols, Inc. Dr Saltvedt has been investigator in the drug trial Boehringer-Ingelheim 1346.0023 Ole A. Andreassen: Consultant to HEALTHLYTIX, speaker honoraria from Lundbeck.
Clinical Protocols
https://clinicaltrials.gov/ct2/show/NCT00594568
https://clinicaltrials.gov/ct2/show/NCT00762411
https://clinicaltrials.gov/ct2/show/NCT00905372
https://clinicaltrials.gov/ct2/show/NCT00904683
https://clinicaltrials.gov/ct2/show/NCT00051909
https://clinicaltrials.gov/ct2/show/NCT00843518
https://clinicaltrials.gov/ct2/show/NCT00191009
https://clinicaltrials.gov/ct2/show/NCT01900665
Funding Statement
RAS: AG027224 and MH116046 BD: MH057881 MIK: AG030653 and AG041718 OLL: AG066468 MB and AR: European Union/EFPIA Innovative Medicines Initiative Joint Undertaking ADAPTED-Grant No 115975, MOPEAD-Grant No. 115985, PI13/02434, I16/01861, PI17/01474, PI19/01301, and CIBERNED grant 2019/08 The genotyping service to generate GRatACE GWAS data: grant PT17/0019 of the PE I+D+i 2013-2016, funded by ISCIII and ERDF National Centralized Repository for Alzheimers Disease and Related Dementias (NCRAD): U24 AG021886 The NACC database: NIA/NIH Grant U01 AG016976 The Alzheimers Disease Genetics Consortium (ADGC): NIA grants U01AG032984 and RC2AG036528 National Institute on Aging Alzheimers Disease Data Storage Site (NIAGADS): U24-AG041689-01 NEXGENS: National Institute on Aging of the National Institutes of Health R01AG067015 AddNeuroMed: EU FP6 program as part of InnoMed NorCog: South-Eastern Norway Regional Health Authority and Norwegian National Advisory Unit on Ageing and Health HMS: the Norwegian Institute of Public Health, the Norwegian University of Science and Technology (NTNU), Nord-Trøndelag Hospital Trust, and Innlandet Hospital Trust REDIC-NH: Age-Related Functional Decline and Disease, Innlandet Hospital Trust, and the Norwegian Health Directorate NIMH: U01 MH46281, U01 MH46290, U01 MH46373 Ole A. Andreassen: Research Council of Norway #223273
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Collection of all clinical data and genetic samples were approved by the Institutional Review Board or Medical Ethics Committee, as appropriate, for each source program
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Data will be submitted to NIAGADS (https://www.niagads.org) upon acceptance of peer-reviewed manuscript.
http://csg.sph.umich.edu/abecasis/metal/index.html
http://www.compgen.pitt.edu/GemTools/GemTools.htm
https://www.cog-genomics.org/plink2/
https://ftp.ncbi.nih.gov/snp/redesign/latest_release/VCF/
http://ldsc.broadinstitute.org/ldhub/
https://imputation.sanger.ac.uk
